SCHEMBL4806535

SCHEMBL4806535

NC(=O)c1ccccc1C[CH]c1cc(-c2cccc(O)c2)ccn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.40
CHEK1 O14757 1/20 0.38
PAK4 O96013 1/20 0.38
CSNK2A2 P19784 1/20 0.38
CDK2 P24941 1/20 0.38
MAPK1 P28482 1/20 0.38
AKT1 P31749 1/20 0.38
MAPK8 P45983 1/20 0.38
PLK1 P53350 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
MAP2K1 Q02750 1/20 0.38
AKR1C3 P42330 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
IKBKB O14920 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5168511 0.90 SIRT2 (0.42) PARP1CDK2MAP2K1SIRT2SIRT1
SCHEMBL4804892 0.88 MAP4K4 (0.46) PARP1SIRT2SIRT1IKBKBKDM4E
SCHEMBL4797881 0.86 MKNK2 (0.47) IKBKBKDM4EALDH1A1HPGDHSD17B10
SCHEMBL4806388 0.79 CSF1R (0.37) CHEK1MAPK1MAPK8CDC7JAK2
SCHEMBL4803121 0.78 F11 (0.41) KDM4EALDH1A1HPGDHSD17B10BTK
SCHEMBL4798614 0.78 PDPK1 (0.47) CHEK1CDK2JAK2JAK3AURKA
SCHEMBL4809955 0.78 CYP11B2 (0.45) CDC7BTK
SCHEMBL4796029 0.76 ACVR1 (0.47) PARP1SYK
SCHEMBL4797142 0.76 GPR52 (0.38) PARP1IKBKBCDC7BTKCHUK
SCHEMBL4650174 0.75 KMO (0.43) PARP1SIRT2SIRT1IKBKBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429604-B2 Six-membered heterocycles useful as serine protease inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2008-09-30 US disclosed
EP-1773775-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-04-18 EP disclosed
US-20060009455-A1 especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; BRISTOL-MYERS SQUIBB COMPANY 2006-01-12 US disclosed
WO-2005123680-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009455-A1 especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; F12, F11, F2 PARP1 2559/4885CHEK1 3854/4885PAK4 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.